2004, Computational Chemistry and Marketing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2004

Computational Chemistry

Marketing

Sygnature Discovery accelerates global growth with major North American acquisition

Sygnature Discovery

JULY 31, 2023

This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader. Since 2004, Sygnature Discovery has delivered over 40 novel pre-clinical and 22 clinical compounds, with its scientists named on over 170 patents.

Computational Chemistry

Computational Chemistry Science Clinical Trials Pharmaceutical Companies

How the AI revolution can accelerate early drug discovery

Drug Target Review

SEPTEMBER 20, 2023

Author bio: Matthew Habgood Principal Computational Chemist, Cresset Matthew graduated from Imperial College London in 2004 with an MSci in Chemistry and was co-awardee of the Neil Arnott prize for best chemistry graduate at the University of London. Rob is a Fellow of the Royal Society of Chemistry.

Drugs

Drugs Metabolic Stability Computational Chemistry Pharmaceuticals

Drug Discovery Digest

Sygnature Discovery accelerates global growth with major North American acquisition

How the AI revolution can accelerate early drug discovery

Stay Connected